Andrea Moerman-Herzog

Andrea Moerman-Herzog


Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2016 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
HCHannah N. Coleman
Hannah N. Coleman
WGWilliam W. Greenfield
William W. Greenfield
SSShawna L. Stratton
Shawna L. Stratton
RVRita Vaughn
Rita Vaughn
AKAlexander Kieber
Alexander Kieber
MNMayumi Nakagawa
Mayumi Nakagawa

1 January 2009 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
XMXianrong R. Mao
Xianrong R. Mao
AMAndrea Moerman-Herzog
Andrea Moerman-Herzog
YCYuzhi Chen
Yuzhi Chen
SBSteven Barger
Steven Barger
The unique physiology and function of neurons create differences in their cellular physiology, including their regulation of gene expression. We began several years ago exploring the relationships between the NFκB transcription factor, neuronal survival, and glutamate receptor activation in telencephalic neurons. These studies led us to conclude that this population of cells is nearly incapable of activating the NFκB that is nonetheless expressed at reasonable levels. A subset of the κB cis elements are instead bound by members of the Sp1 family in neurons. Also surprising was our discovery that Sp1 itself, typically described as ubiquitous, is severely restricted in expression within forebrain neurons; Sp4 seems to be substituted during neuronal differentiation. These findings and their implications for neuronal differentiation – as well as potential dedifferentiation during degenerative processes – are discussed here.

27 May 2015 in OncoImmunology
Verified
Journal Article
Open access
WGWilliam W Greenfield
William W Greenfield
SSShawna L Stratton
Shawna L Stratton
RMRebecca S Myrick
Rebecca S Myrick
RVRita Vaughn
Rita Vaughn
LDLisa M Donnalley
Lisa M Donnalley
MNMayumi Nakagawa
Mayumi Nakagawa
PURPOSE: Non-surgical treatments for cervical intraepithelial neoplasia 2/3 (CIN2/3) are needed as surgical treatments have been shown to double preterm delivery rate. The goal of this study was to demonstrate safety of a human papillomavirus (HPV) therapeutic vaccine called PepCan, which consists of four current good-manufacturing production-grade peptides covering the HPV type 16 E6 protein and Candida skin test reagent as a novel adjuvant. PATIENTS AND METHODS: The study was a single-arm, single-institution, dose-escalation phase I clinical trial, and the patients (n = 24) were women with biopsy-proven CIN2/3. Four injections were administered intradermally every 3 weeks in limbs. Loop electrical excision procedure (LEEP) was performed 12 weeks after the last injection for treatment and histological analysis. Six subjects each were enrolled (50, 100, 250, and 500 μg per peptide). RESULTS: The most common adverse events (AEs) were injection site reactions, and none of the patients experienced dose-limiting toxicities. The best histological response was seen at the 50 μg dose level with a regression rate of 83% (n = 6), and the overall rate was 52% (n = 23). Vaccine-induced immune responses to E6 were detected in 65% of recipients (significantly in 43%). Systemic T-helper type 1 (Th1) cells were significantly increased after four vaccinations (P = 0.02). CONCLUSION: This study demonstrated that PepCan is safe. A significantly increased systemic level of Th1 cells suggests that Candida, which induces interleukin-12 (IL-12) in vitro, may have a Th1 promoting effect. A phase II clinical trial to assess the full effect of this vaccine is warranted.

1 August 2015 in Clinical and Vaccine Immunology
Verified
Journal Article
Open access
PDF file
AMAndrea Moerman-Herzog
Andrea Moerman-Herzog
MNMayumi Nakagawa
Mayumi Nakagawa
Cervical cancer is the fourth most common cancer in women and is almost exclusively caused by human papillomavirus (HPV) infection. HPV is also frequently associated with other cancers arising from mucosal epithelium, including anal and oropharyngeal cancers, which are becoming more common in both men and women. Viral persistence and progression through precancerous lesion stages are prerequisites for HPV-associated cancer and reflect the inability of cell-mediated immune mechanisms to clear infections and eliminate abnormal cells in some individuals. Cell-mediated immune responses are initiated by innate pathogen sensing and subsequent secretion of soluble immune mediators and amplified by the recruitment and activation of effector T lymphocytes. This review discusses early defensive mechanisms of innate responders to natural HPV infection, their influence on response polarization, and the underappreciated role of keratinocytes in this process.

1 November 2006 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
XMXianrong Mao
Xianrong Mao
AMAndrea Moerman-Herzog
Andrea Moerman-Herzog
WWWei Wang
Wei Wang
SBSteven Barger
Steven Barger
In addition to their conventional G-C/T target sequences, Sp1 family transcription factors (Sp-factors) can interact with a subset of the target sequences for NFκB. Due to the low level of bona fide NFκB activity in most resting cells, this interaction between Sp-factors and κB-sites could play important roles in cell function. Here we used mutagenesis of a canonical κB element from the immunoglobulin and HIV promoters to identify the GC-rich sequences at each end required for Sp-factor targeting. Through screening of multiple κB elements, a sequence element located in the second intron of superoxide dismutase-2 (SOD2) was identified as a good candidate for both NFκB and Sp-factor binding. In neurons, the prominent proteins interacting with this site were Sp3 and Sp4, whereas Sp1, Sp3, and NFκB were associated with this site in astroglia. The neuronal Sp-factors repressed transcriptional activity through this κB-site. In contrast, astroglial Sp-factors activated promoter activity through the same element. NFκB contributed to control of the SOD2 κB element only in astrocytes. These findings imply that cell-type specificity of transcription in the central nervous system, particularly with regard to κB elements, may include two unique aspects of neurons: 1) a recalcitrant NFκB and 2) the substitution of Sp4 for Sp1.

1 April 1999 in Molecular Brain Research
Verified
Journal Article
Closed access
AMAndrea Moerman-Herzog
Andrea Moerman-Herzog
XMXianrong Mao
Xianrong Mao
MLMandy M Lucas
Mandy M Lucas
SBSteven Barger
Steven Barger